Novel and Future Developments in Epigenetic Therapy for Cancer

Dear Colleagues,

The alterations in the epigenetic landscape are considered to be a hallmark of cancer. Current research shows that large-scale reprogramming of epigenetic mechanism of cancer cells involves DNA methylation, histone modifications, dynamic assembly of chromatin remodeling complex, nucleosome localization and non-coding RNAs expression. Cancer cells often exhibit alterations in the enzymatic activity of epigenetic factors, showing aberrant modifications of histone and non-histone proteins which contribute to cancer progression. In recent years, continuous research efforts have resulted in the development of tailor-made cancer epigenetic therapy, which is now regarded as the future of precision medicine. Overall, a growing body of evidence indicates that SMYD3 is an essential epigenetic regulator that methylates histone and non-histone substrates, orchestrating protein–protein and protein–DNA interactions; however, its epigenetic role in cancer is not yet fully understood.

This Special Issue aims to collate relevant papers, original research as well as reviews, that highlight the recent and future developments in epigenetic therapy for cancer.

Dr. Paola Sanese
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• epigenetic reprogramming
• epigenetic therapy
• cancers
• epigenomics
• precision medicine
• chromatin dynamics
• epigenetic plasticity